INNA-051 Influenza Challenge Study

Influenza Prophylaxis Clinical Trial

Official title: Phase 2a Study in Healthy Adult Participants Pre-treated With INNA-051 and Challenged With Influenza Virus

Status Completed

Clinical Trial Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Clinical Trial Description

Healthy participants will be administered 2 doses on INNA-051 intra-nasally and subsequently administered influenza virus as a challenge. Participants will be quarantined for 8 days. Study assessments will be performed during this period and they will monitored for symptoms of influenza infection. ;

Related Conditions & MeSH terms

• Influenza Prophylaxis
• Influenza, Human

• NCT number: NCT05255822
• Study type: Interventional
• Source: ENA Respiratory Pty Ltd
• Status: Completed
• Phase: Phase 2
• Start date: February 28, 2022
• Completion date: August 23, 2022